JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.
JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.